Drug Profile
Sirolimus-eluting coronary stent - REVA Medical
Alternative Names: Fantom; Fantom bioresorbable vascular scaffold; Fantom Encore; ReZolve; ReZolve Scaffold; ReZolve2Latest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator REVA Medical
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 04 Apr 2023 No development reported - Clinical-Phase-Unknown for Coronary artery restenosis in Brazil (Intracoronary)
- 30 Apr 2020 REVA Medical completes FANTOM I trial for Fantom™ bioresorbable coronary scaffold in native coronary arteries in Brazil and Poland (NCT02512003)
- 31 Jan 2019 REVA Medical completes RESTORE II clinical trial for coronary artery stenosis in Australia, Brazil, and Germany (NCT01845311)